Obesity, dyslipidemia, and cardiovascular disease: A joint expert review from the Obesity Medicine Association and the National Lipid Association 2024

Keyphrases

• Obesity 100%
• Cardiovascular Risk 100%
• Obesity-related Diseases 100%
• Expert Review 100%
• Obesity Medicine 100%
• National Lipid Association 100%
• Adipose Tissue 66%
• High-density Lipoprotein Cholesterol (HDL-C) 66%
• Low-density Lipoprotein Cholesterol (LDL-C) 66%
• Non-high-density Lipoprotein Cholesterol (non-HDL-C) 66%
• Excess Adiposity 66%
• Weight Reduction 33%
• Pathophysiologic 33%
• Obesity Intervention 33%
• Risk Reduction 33%
• Total-body 33%
• Dyslipidemia 33%
• Early Intervention 33%
• Population-based Study 33%
• Peer Review 33%
• Low-density Lipoprotein Cholesterol Level 33%
• Triglycerides 33%
• Adiposity 33%
• Lipid Levels 33%
• Overweight or Obesity 33%
• Body Fat Percentage 33%
• Cardiometabolic Risk 33%
• Particle Concentration 33%
• Clinical Perspective 33%
• Small Dense LDL 33%
• Apolipoprotein B (Apo B) 33%
• Patients with Obesity 33%
• Clinical Considerations 33%
• Cardiovascular Outcomes 33%
• Free Cholesterol 33%
• LDL Particle Size 33%
• Elevated Triglycerides 33%
• Lipid Species 33%
• Atherogenic Lipid Profile 33%

Medicine and Dentistry

• Dyslipidemia 100%
• Cardiovascular Disease 100%
• Obesity Medicine 100%
• High Density Lipoprotein Cholesterol 60%
• Obesity 60%
• Adipose Tissue 60%
• Low Density Lipoprotein Cholesterol 60%
• Triacylglycerol 40%
• Patient with Obesity 40%
• Population Research 20%
• Clinician 20%
• Early Intervention 20%
• Cardiometabolic Risk 20%
• Body Weight 20%
• Body Fat 20%
• Apolipoprotein B 20%
• Tissue Expansion 20%
• Patient with Overweight 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Dyslipidemia 100%
• Cardiovascular Disease 100%
• Obesity 80%
• High Density Lipoprotein Cholesterol 60%
• Low Density Lipoprotein Cholesterol 60%
• Triacylglycerol 40%
• Population Study 20%
• Apolipoprotein B 20%